Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Labcorp (LH)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
$363.30-1.22%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
19.89 → 19.72 EPS · FY ending Dec 31, 2027 · 12 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 12 to 12; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for LH yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Adjusted EPS near $18 in 2026 | A primary condition in Labcorp's published investment case. The stated target is >= $17.98 per share. | Intact | Adjusted EPS falls below $17.0 in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
LH is a healthcare diagnostics business with a relatively steady operating base and some exposure to economic cycles. Its long-term thesis is intact, with recent performance in the top half of its industry, though management execution has been volatile.
The valuation evidence describes LH as cheap versus peers, with a modest expectations gap and no signs of elevated pricing fragility. The evidence suggests the valuation is justified, but it does not specify which growth or margin expectations are already built in.
Near term, the latest results and an earnings beat support the current operating picture. Specialty testing and Diagnostics Laboratories revenue both grew year over year, alongside new offerings and customer-related activity. A recent guidance increase raises the stakes: reversing it could damage credibility, while weakening job growth could add pressure to cyclical healthcare demand.
The multi-year view hinges on continued execution in specialty testing and partnerships with health systems and laboratories. Near term, a guidance reversal or further weakening in jobs would be unfavorable; continued strong results and guidance from sector peers would support the healthcare backdrop.
Over the next 1 to 3 years, LH has a supported but not risk-free thesis: recent business performance is strong, while management credibility and economic conditions remain important swing factors. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Free cash flow is strong at about $1.3 billion. |
| Intact |
| Free cash flow falls below $1.1 billion in FY26 |
Free cash flow: $412.2M FY2026-Q3; GAAP. Published target: ~$1.3 billion. Annual target cannot be compared with a quarterly or TTM observation. Oct 30, 2026412,200,000 USD · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Growth from AI tools and oncology partnerships | New AI tools and cancer trial partnerships support growth. | Intact | No revenue growth from AI or oncology partnerships in 2026 | Qualitative: AI app launched (May) & Oncology partnerships active (Jun/Sep) AI app launch, colorectal cancer trial partnership, and MLM Medical Labs acquisition reinforce specialty testing and oncology growth. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue grows about 6% to ~$14.72 billion in 2026 | Labcorp grows revenue about 6% a year. | Intact | Revenue falls below $13.9 billion in FY26 | Revenue: $3.81B FY2026-Q3; GAAP. Published target: ~$14.72 billion. Annual target cannot be compared with a quarterly or TTM observation. Oct 30, 20263,810,000,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$19.41 → $19.72 · observed estimates
$15.42B → $15.64B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $19.41 | $15,417,593,790 | 19 / 17 |
| 2026-07-25 | $19.46 | $15,417,706,390 | 12 / 14 |
| 2026-07-26 | $19.41 | $15,417,593,790 | 19 / 17 |
| 2026-07-27 | $19.41 | $15,417,593,790 | 19 / 17 |
| 2026-07-28 | $19.41 | $15,417,593,790 | 19 / 17 |
| 2026-07-29 | $19.46 | $15,404,953,035 | 12 / 14 |
| 2026-07-30 | $19.41 | $15,417,593,790 | 19 / 17 |
| 2026-07-31 | $19.67 | $15,454,148,542 | 12 / 14 |
| 2026-08-01 | $19.67 | $15,454,148,542 | 12 / 14 |
| 2026-08-02 | $19.78 | $15,460,290,642 | 12 / 14 |
| 2026-08-03 | $19.75 | $15,456,425,860 | 18 / 16 |
| 2026-08-04 | $19.75 | $15,456,425,860 | 18 / 16 |
| 2026-08-05 | $19.75 | $15,456,428,080 | 18 / 16 |
| 2026-08-06 | $19.75 | $15,456,428,080 | 18 / 16 |
| 2026-08-07 | $19.78 | $15,460,290,642 | 12 / 14 |
| 2026-08-08 | $19.76 | $15,458,309,410 | 18 / 16 |
| 2026-08-09 | $19.78 | $15,464,003,160 | 18 / 16 |
| 2026-08-10 | $19.78 | $15,460,290,642 | 12 / 14 |
| 2026-08-12 | $19.78 | $15,464,003,160 | 18 / 16 |
| 2026-08-13 | $19.78 | $15,460,290,642 | 12 / 14 |
| 2026-08-14 | $19.78 | $15,460,290,642 | 12 / 14 |
| 2026-08-15 | $19.78 | $15,460,290,642 | 12 / 14 |
| 2026-08-16 | $19.78 | $15,460,290,642 | 12 / 14 |
| 2026-08-17 | $19.78 | $15,460,290,642 | 12 / 14 |
| 2026-08-18 | $19.78 | $15,460,290,642 | 12 / 14 |
| 2026-08-19 | $19.78 | $15,460,290,642 | 12 / 14 |
| 2026-08-20 | $19.86 | $15,474,031,599 | 12 / 13 |
| 2026-08-21 | $19.86 | $15,474,031,599 | 12 / 13 |
| 2026-08-22 | $19.86 | $15,474,031,599 | 12 / 13 |
| 2026-08-23 | $19.86 | $15,474,031,599 | 12 / 13 |
| 2026-08-24 | $19.86 | $15,474,031,599 | 12 / 13 |
| 2026-08-25 | $19.86 | $15,474,031,599 | 12 / 13 |
| 2026-08-26 | $19.86 | $15,474,031,599 | 12 / 13 |
| 2026-08-27 | $19.86 | $15,474,031,599 | 12 / 13 |
| 2026-08-28 | $19.86 | $15,474,031,599 | 12 / 13 |
| 2026-08-29 | $19.86 | $15,474,031,599 | 12 / 13 |
| 2026-08-30 | $19.86 | $15,474,031,599 | 12 / 13 |
| 2026-08-31 | $19.86 | $15,474,031,599 | 12 / 13 |
| 2026-09-01 | $19.86 | $15,474,031,599 | 12 / 13 |
| 2026-09-02 | $19.88 | $15,474,031,599 | 12 / 13 |
| 2026-09-03 | $19.88 | $15,474,031,599 | 12 / 13 |
| 2026-09-04 | $19.88 | $15,474,031,599 | 12 / 13 |
| 2026-09-05 | $19.88 | $15,474,031,599 | 12 / 13 |
| 2026-09-06 | $19.88 | $15,474,031,599 | 12 / 13 |
| 2026-09-07 | $19.88 | $15,474,031,599 | 12 / 13 |
| 2026-09-08 | $19.88 | $15,474,031,599 | 12 / 13 |
| 2026-09-09 | $19.88 | $15,474,031,599 | 12 / 13 |
| 2026-09-10 | $19.88 | $15,474,031,599 | 12 / 13 |
| 2026-09-11 | $19.88 | $15,474,031,599 | 12 / 13 |
| 2026-09-12 | $19.90 | $15,480,017,264 | 12 / 13 |
| 2026-09-13 | $19.90 | $15,480,017,264 | 12 / 13 |
| 2026-09-14 | $19.90 | $15,480,017,264 | 12 / 13 |
| 2026-09-15 | $19.90 | $15,480,017,264 | 12 / 13 |
| 2026-09-16 | $19.90 | $15,480,017,264 | 12 / 13 |
| 2026-09-17 | $19.90 | $15,480,017,264 | 12 / 13 |
| 2026-09-18 | $19.90 | $15,480,017,264 | 12 / 13 |
| 2026-09-19 | $19.90 | $15,480,017,264 | 12 / 13 |
| 2026-09-20 | $19.90 | $15,480,017,264 | 12 / 13 |
| 2026-09-21 | $19.90 | $15,480,017,264 | 12 / 13 |
| 2026-09-22 | $19.90 | $15,480,017,264 | 12 / 13 |
| 2026-09-23 | $19.89 | $15,478,329,726 | 12 / 13 |
| 2026-09-24 | $19.89 | $15,478,329,726 | 12 / 13 |
| 2026-09-25 | $19.90 | $15,484,877,603 | 12 / 13 |
| 2026-09-26 | $19.90 | $15,484,877,603 | 12 / 13 |
| 2026-09-27 | $19.90 | $15,484,877,603 | 12 / 13 |
| 2026-09-28 | $19.90 | $15,484,877,603 | 12 / 13 |
| 2026-09-29 | $19.90 | $15,484,877,603 | 12 / 13 |
| 2026-09-30 | $19.90 | $15,484,877,603 | 12 / 13 |
| 2026-10-01 | $19.90 | $15,484,877,603 | 12 / 13 |
| 2026-10-02 | $19.90 | $15,484,877,603 | 12 / 13 |
| 2026-10-03 | $19.89 | $15,483,096,538 | 12 / 13 |
| 2026-10-04 | $19.89 | $15,483,096,538 | 12 / 13 |
| 2026-10-05 | $19.89 | $15,483,096,538 | 12 / 13 |
| 2026-10-06 | $19.87 | $15,475,667,967 | 12 / 13 |
| 2026-10-07 | $19.87 | $15,475,667,967 | 12 / 13 |
| 2026-10-08 | $19.87 | $15,475,667,967 | 12 / 13 |
| 2026-10-09 | $19.83 | $15,468,439,395 | 12 / 13 |
| 2026-10-10 | $19.83 | $15,468,439,395 | 12 / 13 |
| 2026-10-11 | $19.83 | $15,468,439,395 | 12 / 13 |
| 2026-10-12 | $19.83 | $15,468,439,395 | 12 / 13 |
| 2026-10-13 | $19.83 | $15,468,439,395 | 12 / 13 |
| 2026-10-14 | $19.83 | $15,468,439,395 | 12 / 13 |
| 2026-10-15 | $19.83 | $15,468,439,395 | 12 / 13 |
| 2026-10-16 | $19.83 | $15,468,439,395 | 12 / 13 |
| 2026-10-17 | $19.83 | $15,468,439,395 | 12 / 13 |
| 2026-10-18 | $19.83 | $15,468,439,395 | 12 / 13 |
| 2026-10-19 | $19.83 | $15,468,439,395 | 12 / 13 |
| 2026-10-20 | $19.83 | $15,468,439,395 | 12 / 13 |
| 2026-10-21 | $19.83 | $15,468,439,395 | 12 / 13 |
| 2026-10-22 | $19.83 | $15,468,439,395 | 12 / 13 |
| 2026-10-23 | $19.83 | $15,468,439,395 | 12 / 13 |
| 2026-10-24 | $19.83 | $15,468,439,395 | 12 / 13 |
| 2026-10-25 | $19.83 | $15,468,439,395 | 12 / 13 |
| 2026-10-26 | $19.83 | $15,468,439,395 | 12 / 13 |
| 2026-10-27 | $19.83 | $15,468,439,395 | 12 / 13 |
| 2026-10-28 | $19.83 | $15,468,439,395 | 12 / 13 |
| 2026-10-29 | $19.78 | $15,602,997,530 | 12 / 13 |
| 2026-10-30 | $19.70 | $15,611,399,478 | 12 / 13 |
| 2026-10-31 | $19.70 | $15,611,399,478 | 12 / 13 |
| 2026-11-01 | $19.70 | $15,611,399,478 | 12 / 13 |
| 2026-11-02 | $19.70 | $15,611,399,478 | 12 / 13 |
| 2026-11-03 | $19.72 | $15,635,180,172 | 12 / 13 |
| 2026-11-04 | $19.72 | $15,635,180,172 | 12 / 13 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 12 Buy / Strong Buy · 5 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 4 recorded
6 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.